Study design
NSCLC, tumor
TUMOR, NSCLC
As an open-label, multicenter, phase II clinical trial, this study evaluated the clinical activity and safety of neoadjuvant nivolumab-exclusive and nivolumab–chemotherapy combinations for resectable NSCLC based on the tumor expression of PD-L1 at the baseline (NCT04015778). The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice, and approved by the clinical research ethics committee of each participating center. All patients provided written informed consents prior to enrollment. The full study protocol is provided as a 